Company Filing History:
8 out of 22 
3 out of 21 
2 out of 35 
Years Active: 2016-2025
Title: **Exploring the Innovations of Glenn E. Dale in Convertible Rifabutin Treatment**
Introduction
Glenn E. Dale is a distinguished inventor hailing from Basel, Switzerland. With a remarkable portfolio of 13 patents, Dale has significantly contributed to the field of pharmaceuticals, particularly in the treatment of bacterial infections. His innovative approaches to rifabutin treatment showcase his commitment to advancing medical science.
Latest Patents
Among Glenn E. Dale’s latest patents is one focused on rifabutin treatment methods, uses, and compositions. This invention introduces systems and methods designed to enhance the clinical efficacy of rifabutin against infections. The groundbreaking aspect of the invention lies in the recognition of the ferric-coprogen (FhuE) receptor, which facilitates the uptake of rifabutin into cells. His patented methods include obtaining a sample from a patient suspected of an infection, performing tests to identify the infection, and providing a formulation of rifabutin that optimizes clinical outcomes when administered. The formulation is ideally delivered via intravenous injection, targeting a concentration of greater than 2 mg/L, and not exceeding 50 mg/L. Additionally, Dale has developed formulations consisting of highly concentrated solutions of rifabutin, which can be used therapeutically to combat bacterial infections effectively.
Career Highlights
Glenn E. Dale has garnered experience working with notable companies such as Bioversys AG and Emergent Product Development Gaithersburg Inc. His work at these organizations has enabled him to develop innovative solutions and contribute to advancements in medical treatments and pharmaceuticals.
Collaborations
Throughout his career, Dale has collaborated with talented colleagues, including Sergio Lociuro and Marc Gitzinger. These partnerships have allowed for the exchange of ideas and fostered an environment of innovation that has significantly impacted their field.
Conclusion
Glenn E. Dale’s contributions to the field of rifabutin treatment reflect his dedication to medical innovation. With a series of impactful patents and an impressive career spanning several esteemed companies, Dale continues to inspire future generations of inventors and researchers in the pharmaceutical industry. His work underscores the importance of innovation in improving treatment methodologies and patient outcomes.